Bristol Myers’ Reblozyl shows positive results in alpha-thalassemia study

Bristol Myers (BMY) announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study evaluating Reblozyl – luspatercept-aamt – versus placebo for anemia in adults with alpha-Thalassemia. The non-transfusion-dependent ) and transfusion-dependent cohorts of the study met their respective primary endpoints, with Reblozyl demonstrating a statistically significant and clinically meaningful increase in hemoglobin levels in NTD patients with alpha-thalassemia, and a statistically significant and clinically meaningful decrease in red blood cell transfusion burden in TD patients with alpha-thalassemia. The study also met all key secondary endpoints. Safety findings were consistent with the known profile of Reblozyl in thalassemia. The data will be presented at an upcoming medical congress and will be discussed with the Center for Drug Evaluation in China.